Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster or catch-up study of 10-valent pneumococcal conjugate vaccine in Nigerian children previously enrolled in 10PN-PD-DIT-032
2012-000826-23Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 cohorts), sponsored by GSK. Primary endpoint: Occurrence of grade 3 adverse events.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2012-000826-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000826-23.